Phase 1 Trial

Latest News Stock Market

Atisama Therapeutics Advances RB042 Into Multiple Ascending Dose Phase 1 Cohorts, Names Bernard Coulie Board Chair

May 15, 2026
Anil Kumar

Atisama Therapeutics said its lead candidate RB042 has advanced into multiple ascending dose cohorts in a…